In a definitive move to solidify its standing in the global hepatology market, the Italian pharmaceutical group Alfasigma has entered into a definitive agreement with GSK to acquire the global rights to linerixibat, a promising investigational treatment for cholestatic pruritus associated with primary biliary cholangitis (PBC). The deal, valued at an initial $300 million upfront, signals a strategic pivot for Alfasigma, coming just six months after the company was forced to withdraw its previous PBC flagship therapy, Ocaliva, from the United States market. This acquisition not only underscores Alfasigma’s resilience in the rare liver disease space but also highlights a significant shift in GSK’s therapeutic focus as the British drugmaker streamlines its pipeline to prioritize high-prevalence liver conditions.
Under the terms of the agreement, Alfasigma will assume full responsibility for the global development and commercialization of linerixibat. Beyond the initial $300 million payment, GSK is eligible to receive a $100 million milestone payment upon the drug’s potential approval by the U.S. Food and Drug Administration (FDA). The regulatory agency is currently reviewing the New Drug Application (NDA) for linerixibat, with a Prescription Drug User Fee Act (PDUFA) action date set for March 24. Furthermore, the deal includes $20 million in payments contingent upon approvals in the European Union and the United Kingdom, and up to $270 million in commercial milestones based on specific sales targets. GSK will also retain a right to tiered royalties on net sales, ensuring a long-term revenue stream from the asset.
Understanding Primary Biliary Cholangitis and the Burden of Pruritus
Primary biliary cholangitis is a chronic, progressive autoimmune liver disease characterized by the destruction of the small bile ducts within the liver. When these ducts are damaged, bile—a fluid that aids digestion and toxin removal—builds up in the liver, leading to inflammation and scarring (cirrhosis). Over time, this cholestasis results in the leakage of bile acids into the systemic circulation.
While the progression of the disease toward liver failure is a primary clinical concern, patients often identify pruritus, or severe itching, as the most debilitating symptom of the condition. Unlike common skin-related itching, cholestatic pruritus is internal, persistent, and cannot be relieved by scratching. Data from patient advocacy groups and clinical studies suggest that up to 70% of PBC patients experience pruritus at some point during their disease progression. For many, the itch is most severe at night, leading to chronic sleep deprivation, fatigue, and a significantly diminished quality of life. In extreme cases, the psychological toll of unrelenting pruritus has been linked to suicidal ideation, highlighting the critical need for targeted symptomatic relief.
Linerixibat, a small-molecule inhibitor of the ileal bile acid transporter (IBAT), represents a novel approach to addressing this symptom. By blocking the IBAT protein in the small intestine, the drug prevents the reabsorption of bile acids into the bloodstream. This interruption of the enterohepatic circulation effectively lowers the systemic levels of bile acids thought to trigger the itching sensation in PBC patients.
The Evolution of the PBC Treatment Landscape
The acquisition of linerixibat occurs during a period of rapid transformation in the treatment of PBC. For decades, ursodeoxycholic acid (UDCA) was the only approved first-line therapy. However, approximately 40% of patients do not achieve an adequate biochemical response to UDCA, necessitating second-line interventions.
Alfasigma’s previous entry into this market was through its $794 million acquisition of Intercept Pharmaceuticals in 2023. Intercept’s primary asset, Ocaliva (obeticholic acid), was a farnesoid X receptor (FXR) agonist that received accelerated approval from the FDA in 2016. However, Ocaliva’s journey was fraught with regulatory challenges. While it successfully lowered alkaline phosphatase (ALP) levels—a key biomarker of liver cholestasis—it failed to demonstrate a definitive benefit in preventing liver failure or death in long-term studies. Additionally, Ocaliva was known to exacerbate pruritus in some patients, a side effect that limited its utility for those already suffering from severe itching.
The regulatory environment for Ocaliva soured further in 2024 when the FDA issued safety communications regarding risks of liver injury in patients with advanced cirrhosis. This was followed by the European Commission revoking its conditional marketing authorization. By September 2025, Alfasigma and Intercept announced a voluntary withdrawal of the drug from the U.S. market, leaving a vacuum in Alfasigma’s hepatology portfolio.
During this same period, two new competitors entered the fray. In 2024, the FDA granted accelerated approval to Ipsen and Genfit’s Iqirvo (elafibranor) and Gilead Sciences’ Livdelzi (seladelpar). Both of these drugs are peroxisome proliferator-activated receptor (PPAR) agonists. While they have shown impressive results in improving liver biomarkers and, in the case of Livdelzi, providing some relief for pruritus, Alfasigma believes there is a distinct clinical niche for a dedicated IBAT inhibitor like linerixibat.
Clinical Evidence Supporting Linerixibat
The confidence Alfasigma has placed in linerixibat is rooted in the results of the Phase 3 GLISTEN clinical trial. The study was designed to evaluate the efficacy and safety of the drug specifically in patients with PBC who suffer from moderate to severe pruritus. According to data released by GSK, the trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in itch intensity compared to a placebo.
The GLISTEN data showed that patients treated with linerixibat experienced rapid relief, with improvements often noted within the first few weeks of therapy. Importantly, the relief was sustained throughout the duration of the study. Unlike FXR agonists, which can worsen itching, linerixibat’s mechanism of action is specifically tuned to alleviate it by reducing the systemic bile acid load.
The safety profile of linerixibat in the Phase 3 trial was generally consistent with the known effects of IBAT inhibitors. The most common adverse event reported was diarrhea, a predictable result of increased bile acid concentration in the colon due to inhibited absorption in the ileum. However, most cases were reported as mild to moderate and manageable.
Strategic Rationale for Alfasigma and GSK
For Alfasigma, the $300 million investment is a calculated risk to regain its footing in the high-value rare disease market. As a privately held company based in Bologna, Italy, Alfasigma has been aggressively expanding its international footprint. In 2024, the company reported revenues of approximately €1.87 billion ($2.17 billion), representing a 37% year-over-year increase. This growth has been fueled largely by its expansion into the U.S. and its focus on specialty medicines.
"With our deep hepatology expertise and strong global footprint, we are uniquely positioned to lead the worldwide commercialization of linerixibat," stated Francesco Balestrieri, CEO of Alfasigma. "This agreement underscores our strategic focus on bringing meaningful new treatments to patients and improving outcomes for communities around the world."
For GSK, the divestiture of linerixibat is part of a broader strategy to "sharpen focus" on its core therapeutic areas. While GSK has a long history in respiratory and infectious diseases, its recent efforts in hepatology have shifted toward high-prevalence conditions with massive market potential. Specifically, GSK is investing heavily in bepirovirsen, an antisense oligonucleotide currently in Phase 3 trials for the "functional cure" of chronic hepatitis B. The company is also advancing programs for metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver disease (ALD).
By offloading linerixibat, GSK secures an immediate cash infusion and removes the commercialization costs associated with a niche rare disease product, while still maintaining a financial interest through milestones and royalties.
Timeline of Key Events in the PBC Market (2016–2026)
- May 2016: FDA grants accelerated approval to Intercept Pharmaceuticals’ Ocaliva for PBC.
- September 2023: Alfasigma acquires Intercept Pharmaceuticals for $794 million to gain control of Ocaliva.
- June 2024: FDA approves Ipsen and Genfit’s Iqirvo (elafibranor) for second-line PBC treatment.
- August 2024: FDA approves Gilead Sciences’ Livdelzi (seladelpar) for PBC, with data showing pruritus improvement.
- September 2025: Alfasigma voluntarily withdraws Ocaliva from the U.S. market following regulatory setbacks and safety concerns.
- January 2026: Alfasigma announces the acquisition of linerixibat from GSK for $300 million upfront.
- March 24, 2026: Expected FDA PDUFA date for linerixibat.
Broader Implications and Future Outlook
The success of linerixibat could validate the use of IBAT inhibitors in adult liver disease, a class that has already seen success in pediatric populations. Drugs like Ipsen’s Bylvay and Mirum Pharmaceuticals’ Livmarli are currently approved for pruritus in rare pediatric conditions like Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC). Linerixibat would be the first IBAT inhibitor specifically approved for the adult PBC population, potentially setting a new standard of care for symptomatic management.
The move also highlights the increasing fragmentation of the PBC market. While UDCA remains the first-line foundation, the second-line market is now split between PPAR agonists (Iqirvo, Livdelzi) and the potential entry of an IBAT inhibitor (linerixibat). Physicians may soon have the ability to tailor treatments based on a patient’s specific symptoms—prioritizing PPARs for those needing biochemical control and IBAT inhibitors for those whose primary burden is life-altering pruritus.
As the March 24 FDA deadline approaches, the pharmaceutical industry will be watching closely to see if Alfasigma can successfully transition from the Ocaliva era to a new chapter defined by linerixibat. If approved, the drug will not only provide relief to thousands of patients but also cement Alfasigma’s status as a dominant force in global hepatology. For now, the $300 million bet serves as a powerful statement of intent in the high-stakes world of rare disease drug development.
